SEC Form 4 · accession 0001445064-15-000026
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President & CEO · Director
Period of report
Jan 9, 2015
Accepted (ET)
Jan 9, 2015 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 9, 2015 | M | 21,180 | $51.35 | A | 176,357 | D | |
| Ordinary Shares | Jan 9, 2015 | S | 15,720 | $102.00 | D | 160,637 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Options (Right to Buy)F2 | $51.35 | Jan 9, 2015 | M | 21,180 | D | Jan 2, 2015 | Jan 2, 2024 | Ordinary Shares | 21,180 | 63,542 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 4, 2014.
- F2The options representing rights to purchase 84,722 shares became exercisable in four equal installments beginning January 2, 2015.